Business Description
ReNeuron Group PLC
ISIN : GB00BF5G6K95
Description
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 14.71 | |||||
Equity-to-Asset | 0.38 | |||||
Debt-to-Equity | 0.14 | |||||
Debt-to-EBITDA | -0.06 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -23.46 | |||||
Beneish M-Score | -1.12 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -63.9 | |||||
3-Year EBITDA Growth Rate | 35.7 | |||||
3-Year EPS without NRI Growth Rate | 36 | |||||
3-Year FCF Growth Rate | 33.2 | |||||
3-Year Book Growth Rate | -39.8 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
14-Day RSI | 37.74 | |||||
12-1 Month Momentum % | -13.92 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.51 | |||||
Quick Ratio | 1.51 | |||||
Cash Ratio | 1.33 | |||||
Days Sales Outstanding | 622.01 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -20.5 | |||||
Shareholder Yield % | 7.56 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -2466.27 | |||||
Net Margin % | -2037.35 | |||||
FCF Margin % | -2130.07 | |||||
ROE % | -104.53 | |||||
ROA % | -50.91 | |||||
ROIC % | -234.54 | |||||
ROC (Joel Greenblatt) % | -1009.29 | |||||
ROCE % | -118.13 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 17 | |||||
PS Ratio | 6.75 | |||||
PB Ratio | 0.8 | |||||
Price-to-Tangible-Book | 0.85 | |||||
EV-to-EBIT | 0.46 | |||||
EV-to-EBITDA | 0.48 | |||||
EV-to-Revenue | -11.24 | |||||
EV-to-Forward-Revenue | 3.18 | |||||
EV-to-FCF | 0.53 | |||||
Price-to-Net-Current-Asset-Value | 1.13 | |||||
Price-to-Net-Cash | 1.7 | |||||
Earnings Yield (Greenblatt) % | 217.39 | |||||
FCF Yield % | -275.96 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
ReNeuron Group PLC Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.286 | ||
EPS (TTM) (€) | -0.102 | ||
Beta | -52.61 | ||
Volatility % | 5665.06 | ||
14-Day RSI | 37.74 | ||
14-Day ATR (€) | 0.000007 | ||
20-Day SMA (€) | 0.034 | ||
12-1 Month Momentum % | -13.92 | ||
52-Week Range (€) | 0.001 - 0.101 | ||
Shares Outstanding (Mil) | 57.17 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
ReNeuron Group PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
ReNeuron Group PLC Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
ReNeuron Group PLC Frequently Asked Questions
What is ReNeuron Group PLC(FRA:RQE1)'s stock price today?
The current price of FRA:RQE1 is €0.03. The 52 week high of FRA:RQE1 is €0.10 and 52 week low is €0.00.
When is next earnings date of ReNeuron Group PLC(FRA:RQE1)?
The next earnings date of ReNeuron Group PLC(FRA:RQE1) is 2024-08-27 Est..
Does ReNeuron Group PLC(FRA:RQE1) pay dividends? If so, how much?
ReNeuron Group PLC(FRA:RQE1) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |